It's somehow time for our last day of ✨LIVE✨ filmings at this year's @myESMO #ESMO26 Congress! 🎥 Are you in Madrid and presenting key data? Reach out to our team to set up an exclusive interview. We would love to speak with you! Follow along for the latest updates from the meeting and to see who we have in the chair today 👉: onclive.com/conference/esmo-…

⚛️ Both promising responses and safety were shown for torvu-sam in PROC according to updated data from the phase 1/2a FONTANA trial, supporting multiple phase 3 trials. Full details : onclive.com/view/torvutatug-… #ovca #oncology @myESMO #ESMO26

📣 Presidential Symposium Spotlight 📣: Head-to-head vs sotorasib or adagrasib, divarasib improved PFS (9.8 vs 5.7 mo; HR, 0.58) and OS (HR, 0.56) in previously treated KRAS G12C–mutated NSCLC in the phase 3 Krascendo 1 trial. Full @myESMO #ESMO26 data: onclive.com/view/divarasib-i… #lcsm #medtwitter #oncology @UTMDAnderson

✨ Presidential Symposium Spotlight ✨: Sonesitatug vedotin doubled median OS vs investigator’s choice (10.0 vs 5.0 mo; HR, 0.47) in 3L+ CLDN18.2+ gastroesophageal carcinoma in the phase 3 CLARITY-Gastric01 trial, though PFS fell short of significance. Full @myESMO #ESMO26 data: onclive.com/view/clarity-gas… #medtwitter #oncology

✨@myESMO Presidential Symposium Spotlight✨: Head-to-head vs durvalumab + chemo, ivonescimab + gemcitabine/cisplatin improved OS (HR, 0.75), PFS (HR, 0.61), and ORR in first-line advanced biliary tract cancer in the phase 3 HARMONi-GI1 trial. Full #ESMO26 data: onclive.com/view/ivonescimab… #medtwitter #oncology

.@myESMO Presidential Symposium Spotlight: A chemo-free option after osimertinib? In the phase 3 SAFFRON trial, osimertinib + savolitinib improved PFS (HR, 0.55) and OS (HR, 0.68) vs platinum/pemetrexed in EGFR+ NSCLC with MET overexpression/amplification. Full #ESMO26 data: onclive.com/view/saffron-dat… #medtwitter #oncology #lcsm

When the content team wants to spread live, in-depth conference coverage and expert insights, they get creative. 🤔 We are on the ground at #ESMO26 with real-time coverage headed your way. 💥 Visit our site to see it all for yourself! #oncology @myESMO

Couldn't make every session at #ESMO26? 🎥 OncLive's News Network: On Location has you covered, with leading oncologists breaking down the key data from Madrid as it's presented. Catch the latest interviews on hubs.li/Q04Cd_s10👇 @myESMO @CParkMD @BalazsHalmosMD @edgardo_ny @OncHahn @MDAndersonNews @Norton_Health @MontefioreNYC @FLASCO_ORG hubs.li/Q04Cd_nz0

Such a fantastic interview with @DrDanielHeng @AHS_CancerCare on the final LITESPARK-011 analysis of bel/len vs cabo in advanced RCC after anti-PD(L)1 @myESMO #ESMO26 And we also got a photo bomb from the one and only @DrChoueiri @DanaFarber Check OncLive.com!

It's time!! The second Presidential Symposium is officially underway. Check back tonight for live coverage of Krascendo 1, SAFFRON, CLARITY-Gastric 01, and HARMONi-GI1 @myESMO #ESMO26 #Oncology

PAPMET2 Ph2 trial initiated by @SWOG presented by @maughanonc at #ESMO26. Builds upon #PAPMET by adding atezolizumab to cabozantinib for pRCC. Small cohort given rare histological subtype but initial results promising: PFS 25 vs 10mo, ORR 47%, no PD as BOR. Results for ongoing #STELLAR304, #SAMETA & #PAXIPEM nccRCC and pRCC trials eagerly awaited @RWinayak

At #ESMO26? Come meet @montypal at the @cityofhope booth now! Whether you're looking for career advice, mentorship, or want to talk all things oncology, this is your chance. Stop by and say hello! 👋🩺 – at Madrid, Spain

UNION: phase III Chinese 🇨🇳 study of neoadj short course RT and periop CAPOX + camrelizumab (anti-PD1) vs neoadj long course CRT and periop CAPOX in locally advanced #rectalcancer: improved pCR, 3 year DFS (91% vs. 77%, significant), and 3 year OS (96% vs. 90%, NS), interesting results but didn’t use a standard TNT regimen #ESMO26 @myesmo #crcsm

AZUR-1 presented by @AndreaCercek @MSKCancerCenter: dostarlimab x 6 months in locally advanced dMMR/MSI-H #rectalcancer (recently FDA approved): 71% clinical complete response (cCR) rate, 100% durable (2 cCR patients had surgery with path complete response (pCR)), overall 76% had cCR at 12 months or pCR #ESMO26 @myESMO #crcsm

EMT2: perioperative omega-3 polyunsaturated eicosapentaenoic acid (EPA, 4 grams a day!) vs placebo in #colorectalcancer liver metastases undergoing resection (2-4 years of treatment): no change in PFS (primary endpoint) BUT there was improved OS by 30% (5 year OS 62% vs 45%)! Bleeding risk actually higher on placebo arm #ESMO26 @myESMO #crcsm

More is not always better: important NEGATIVE phase III IROCAS study of 6 months of adjuvant mFFX (iri 180, no bolus) vs. FOLFOX in high risk stage III (T4 and/or N2) #colorectalcancer - NO difference in DFS or OS - intensifying chemo in high risk disease unfortunately doesn’t work #ESMO26 @myESMO #crcsm

Rise and shine Madrid, it's time to kick off #ESMO26 day 3️⃣! Be sure to check out yesterday's top data and exclusive expert insights, and stay tuned for more to come! All our coverage here ➡️: onclive.com/conference/esmo-… #oncology @myESMO

Resistance post IO in mRCC remains a challenge. ENPP3 is a novel target expressed highly in ccRCC. Ph 1 study of Xmab819 (ENPP3 x CD3) by @montypal shows compelling ORR at 45.5% and DCR at 81.8% in heavily pre-treated population. Dose-dependent efficacy and side effects (CRS, rash) tail off after priming doses. #ESMO26 @RWinayak – at Madrid, Spain

Final analysis of LITESPARK-011 in advanced RCC: belzutifan + lenvatinib resulted in improved PFS and ORR vs cabozantinib post anti-PD-(L)1. Median DOR: 22.0 vs 11.9 mo with OS trending in favor of experimental arm. Crucially, benefit was seen for pts who had received IO/IO and IO/TKI. @RWinayak #ESMO26